- Home
- PCQ vs ANTX Comparison
PCQ vs ANTX Comparison
Compare PCQ & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCQ | ANTX |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.1M | 172.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PCQ | ANTX |
|---|---|---|
| Price | $8.56 | $4.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 121.4K | ★ 353.1K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 4.63% | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.16 | $1.00 |
| 52 Week High | $9.19 | $6.91 |
Technical Indicators
Market Signals| Indicator | PCQ | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 26.98 | 58.69 |
| Support Level | $8.41 | $3.91 |
| Resistance Level | $8.96 | $5.13 |
| Average True Range (ATR) | 0.06 | 0.36 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 6.11 | 80.00 |
Price Performance
Historical ComparisonAbout PCQ PIMCO California Municipal Income Fund
PIMCO California Municipal Income Fund is a closed-end management investment company. It seeks to provide current income exempt from federal, New York State, and New York City income tax. The fund invests across sectors including healthcare, property, education, Natural Gas, and others.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.